This paper analyzes the historical origins and contents of the “Prices of Herbal Medicines” and “Prices of Prescription Medicines” sections within Gosachalyo (Selected Essentials on Verified Facts, 1554), examining how the accumulation of medical knowledge during the early Joseon dynasty influenced sixteenth century public healthcare services and clinical practices.
These price lists, which detail medicinal herbs and prescription drugs sold by the Jeonuigam (Directorate of Medicine) and the Hyeminseo (Office of Benefiting the People)—the Joseon government’s primary public healthcare institutions—were based on prices established during the reign of King Seongjong (1469-1494), with some subsequent adjustments. By the early sixteenth century, 141 prescriptions had been compiled in Yakmyeong (Names of Medicines). This collection was later annotated by an unknown medical official under the title Chiyobokbeop (Gist and Dosage of Medicine). During the compilation of Gosachalyo in 1553 (the eighth year of King Myeongjong’s reign), royal physician Yang Yesu significantly augmented this repertoire, incorporating numerous contemporary prescriptions and organizing a list of 266 medicines.
While some price adjustments are evident, the listed prices of herbal medicines and prescription drugs remained largely consistent with those established during King Seongjong’s reign. The Joseon government maintained these officially promulgated prices for approximately sixty years—from the late Seongjong period until the publication of the first edition of Gosachalyo in 1554—and this price stability continued into the early seventeenth century. This policy reflects the government’s commitment to ensuring a stable and accessible supply of medicines for the subjects.
Compared to Yakmyeong of the early sixteenth century, the mid-sixteenth-century Gosachalyo contains nearly twice as many prescriptions, covering a broader range of diseases. The newly added prescriptions targeted prevalent societal health threats, such as dysentery, and other previously under-treated illnesses.
Joseon medical practitioners actively engaged medical texts imported from the Ming dynasty, such as Yixue Zhengzhuan (Orthodox Documentations of Medicines, 1515), to meet the growing and diverse medical needs of society. By the mid-sixteenth century, Joseon’s clinical medicine was transitioning from the “Old Prescription” stage—reliant on older compendia like Hejijufang (Formulas from the Imperial Pharmacy, 1148) and Dexiaofang (Effective Formulas, 1337)—to a “New Prescription” stage, characterized by the adoption of the Ming dynasty’s medical knowledge. These sixteenth-century imports not only revolutionized Joseon’s clinical practices but also significantly impacted the government’s public health initiatives.

This paper analyzes the historical origins and contents of the “Prices of Herbal Medicines” and “Prices of Prescription Medicines” sections within Gosachalyo (Selected Essentials on Verified Facts, 1554), examining how the accumulation of medical knowledge during the early Joseon dynasty influenced sixteenth century public healthcare services and clinical practices.
These price lists, which detail medicinal herbs and prescription drugs sold by the Jeonuigam (Directorate of Medicine) and the Hyeminseo (Office of Benefiting the People)—the Joseon government’s primary public healthcare institutions—were based on prices established during the reign of King Seongjong (1469-1494), with some subsequent adjustments. By the early sixteenth century, 141 prescriptions had been compiled in Yakmyeong (Names of Medicines). This collection was later annotated by an unknown medical official under the title Chiyobokbeop (Gist and Dosage of Medicine). During the compilation of Gosachalyo in 1553 (the eighth year of King Myeongjong’s reign), royal physician Yang Yesu significantly augmented this repertoire, incorporating numerous contemporary prescriptions and organizing a list of 266 medicines.
While some price adjustments are evident, the listed prices of herbal medicines and prescription drugs remained largely consistent with those established during King Seongjong’s reign. The Joseon government maintained these officially promulgated prices for approximately sixty years—from the late Seongjong period until the publication of the first edition of Gosachalyo in 1554—and this price stability continued into the early seventeenth century. This policy reflects the government’s commitment to ensuring a stable and accessible supply of medicines for the subjects.
Compared to Yakmyeong of the early sixteenth century, the mid-sixteenth-century Gosachalyo contains nearly twice as many prescriptions, covering a broader range of diseases. The newly added prescriptions targeted prevalent societal health threats, such as dysentery, and other previously under-treated illnesses.
Joseon medical practitioners actively engaged medical texts imported from the Ming dynasty, such as Yixue Zhengzhuan (Orthodox Documentations of Medicines, 1515), to meet the growing and diverse medical needs of society. By the mid-sixteenth century, Joseon’s clinical medicine was transitioning from the “Old Prescription” stage—reliant on older compendia like Hejijufang (Formulas from the Imperial Pharmacy, 1148) and Dexiaofang (Effective Formulas, 1337)—to a “New Prescription” stage, characterized by the adoption of the Ming dynasty’s medical knowledge. These sixteenth-century imports not only revolutionized Joseon’s clinical practices but also significantly impacted the government’s public health initiatives.

Purpose: While fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head. Materials and Methods: We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens. Results: A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy. Conclusion Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.

This paper analyzes the historical origins and contents of the “Prices of Herbal Medicines” and “Prices of Prescription Medicines” sections within Gosachalyo (Selected Essentials on Verified Facts, 1554), examining how the accumulation of medical knowledge during the early Joseon dynasty influenced sixteenth century public healthcare services and clinical practices.
These price lists, which detail medicinal herbs and prescription drugs sold by the Jeonuigam (Directorate of Medicine) and the Hyeminseo (Office of Benefiting the People)—the Joseon government’s primary public healthcare institutions—were based on prices established during the reign of King Seongjong (1469-1494), with some subsequent adjustments. By the early sixteenth century, 141 prescriptions had been compiled in Yakmyeong (Names of Medicines). This collection was later annotated by an unknown medical official under the title Chiyobokbeop (Gist and Dosage of Medicine). During the compilation of Gosachalyo in 1553 (the eighth year of King Myeongjong’s reign), royal physician Yang Yesu significantly augmented this repertoire, incorporating numerous contemporary prescriptions and organizing a list of 266 medicines.
While some price adjustments are evident, the listed prices of herbal medicines and prescription drugs remained largely consistent with those established during King Seongjong’s reign. The Joseon government maintained these officially promulgated prices for approximately sixty years—from the late Seongjong period until the publication of the first edition of Gosachalyo in 1554—and this price stability continued into the early seventeenth century. This policy reflects the government’s commitment to ensuring a stable and accessible supply of medicines for the subjects.
Compared to Yakmyeong of the early sixteenth century, the mid-sixteenth-century Gosachalyo contains nearly twice as many prescriptions, covering a broader range of diseases. The newly added prescriptions targeted prevalent societal health threats, such as dysentery, and other previously under-treated illnesses.
Joseon medical practitioners actively engaged medical texts imported from the Ming dynasty, such as Yixue Zhengzhuan (Orthodox Documentations of Medicines, 1515), to meet the growing and diverse medical needs of society. By the mid-sixteenth century, Joseon’s clinical medicine was transitioning from the “Old Prescription” stage—reliant on older compendia like Hejijufang (Formulas from the Imperial Pharmacy, 1148) and Dexiaofang (Effective Formulas, 1337)—to a “New Prescription” stage, characterized by the adoption of the Ming dynasty’s medical knowledge. These sixteenth-century imports not only revolutionized Joseon’s clinical practices but also significantly impacted the government’s public health initiatives.

Purpose: While fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head. Materials and Methods: We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens. Results: A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy. Conclusion Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.

Purpose: While fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head. Materials and Methods: We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens. Results: A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy. Conclusion Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.

This paper analyzes the historical origins and contents of the “Prices of Herbal Medicines” and “Prices of Prescription Medicines” sections within Gosachalyo (Selected Essentials on Verified Facts, 1554), examining how the accumulation of medical knowledge during the early Joseon dynasty influenced sixteenth century public healthcare services and clinical practices.
These price lists, which detail medicinal herbs and prescription drugs sold by the Jeonuigam (Directorate of Medicine) and the Hyeminseo (Office of Benefiting the People)—the Joseon government’s primary public healthcare institutions—were based on prices established during the reign of King Seongjong (1469-1494), with some subsequent adjustments. By the early sixteenth century, 141 prescriptions had been compiled in Yakmyeong (Names of Medicines). This collection was later annotated by an unknown medical official under the title Chiyobokbeop (Gist and Dosage of Medicine). During the compilation of Gosachalyo in 1553 (the eighth year of King Myeongjong’s reign), royal physician Yang Yesu significantly augmented this repertoire, incorporating numerous contemporary prescriptions and organizing a list of 266 medicines.
While some price adjustments are evident, the listed prices of herbal medicines and prescription drugs remained largely consistent with those established during King Seongjong’s reign. The Joseon government maintained these officially promulgated prices for approximately sixty years—from the late Seongjong period until the publication of the first edition of Gosachalyo in 1554—and this price stability continued into the early seventeenth century. This policy reflects the government’s commitment to ensuring a stable and accessible supply of medicines for the subjects.
Compared to Yakmyeong of the early sixteenth century, the mid-sixteenth-century Gosachalyo contains nearly twice as many prescriptions, covering a broader range of diseases. The newly added prescriptions targeted prevalent societal health threats, such as dysentery, and other previously under-treated illnesses.
Joseon medical practitioners actively engaged medical texts imported from the Ming dynasty, such as Yixue Zhengzhuan (Orthodox Documentations of Medicines, 1515), to meet the growing and diverse medical needs of society. By the mid-sixteenth century, Joseon’s clinical medicine was transitioning from the “Old Prescription” stage—reliant on older compendia like Hejijufang (Formulas from the Imperial Pharmacy, 1148) and Dexiaofang (Effective Formulas, 1337)—to a “New Prescription” stage, characterized by the adoption of the Ming dynasty’s medical knowledge. These sixteenth-century imports not only revolutionized Joseon’s clinical practices but also significantly impacted the government’s public health initiatives.

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Background: Turner syndrome (TS) is a common chromosomal abnormality, which is caused by loss of all or part of one X chromosome. Hormone replacement therapy in TS is important in terms of puberty, growth and prevention of osteoporosis however, such a study has never been conducted in Korea. Therefore, the purpose of our study was to determine relationship between the starting age, duration of estrogen replacement therapy (ERT) in TS and develop a hormone replacement protocol suitable for the situation in Korea. Methods: This is retrospective study analyzed the medical records in TS patients treated at the Severance hospital, Yonsei University College of Medicine, Seoul, Korea from 1997 to 2019. Total of 188 subjects who had received a bone density test at least once were included in the study. Korean National Health and Nutrition Examination Survey (KNHANES) was used for achieving bone mineral density (BMD) of normal control group. Student’s t-test, MannWhitney U test, ANOVA and correlation analysis were performed using SPSS 18.0. Results: Each BMD measurement was significantly lower in women with TS than in healthy Korean women. Early start and longer duration of ERT is associated with higher lumbar spine BMD but not femur neck BMD. Femur neck BMD, but not lumbar spine BMD was significantly higher in women with mosaicism than 45XO group. Conclusion Early onset and appropriate duration of hormone replacement therapy is important for increasing bone mineral density in patients with Turner syndrome. Also, ERT affects differently to TS patients according to mosaicism.